Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Drug development in the era of precision medicine
SA Dugger, A Platt, DB Goldstein - Nature reviews Drug discovery, 2018 - nature.com
For the past three decades, the use of genomics to inform drug discovery and development
pipelines has generated both excitement and scepticism. Although earlier efforts …
pipelines has generated both excitement and scepticism. Although earlier efforts …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
BJ Druker, M Talpaz, DJ Resta, B Peng… - … England Journal of …, 2001 - Mass Medical Soc
Background BCR-ABL is a constitutively activated tyrosine kinase that causes chronic
myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming …
myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming …
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien, F Guilhot, RA Larson… - … England Journal of …, 2003 - Mass Medical Soc
Background Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …
response rates in patients with chronic-phase chronic myeloid leukemia (CML) who have …
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien… - … England Journal of …, 2006 - Mass Medical Soc
Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
Direct effects of type I interferons on cells of the immune system
S Hervas-Stubbs, JL Perez-Gracia, A Rouzaut… - Clinical Cancer …, 2011 - AACR
Abstract Type I interferons (IFN-I) are well-known inducers of tumor cell apoptosis and
antiangiogenesis via signaling through a common receptor interferon alpha receptor …
antiangiogenesis via signaling through a common receptor interferon alpha receptor …
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
H Kantarjian, C Sawyers, A Hochhaus… - … England Journal of …, 2002 - Mass Medical Soc
Background Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …
kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a …
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus… - Blood, 2006 - ashpublications.org
The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …